

CADTH RAPID RESPONSE REPORT:
SUMMARY WITH CRITICAL APPRAISAL

Video-Oculography for the Diagnosis of Ocular Myasthenia Gravis: A Review of Diagnostic Accuracy, Cost- Effectiveness, and Guidelines

Service Line:	Rapid Response Service
Version:	1.0
Publication Date:	June 19, 2019
Report Length:	9 Pages

Authors: Yi-Sheng Chao, Charlene Argáez

Cite As: *Video-oculography for the diagnosis of ocular myasthenia gravis: a review of diagnostic accuracy, cost-effectiveness, and guidelines*. Ottawa: CADTH; 2019 Jun. (CADTH rapid response report: summary with critical appraisal).

ISSN: 1922-8147 (online)

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to Requests@CADTH.ca

Context and Policy Issues

Myasthenia gravis is an autoimmune disorder characterized by muscle weakness, as a result of neuromuscular transmission impairment;¹ the fluctuating muscle weakness generally occurs in voluntary skeletal muscles, and varies in severity between patients.² The prevalence is estimated to be 77.7 per million persons according to a meta-analysis of epidemiologic studies published between 1950 and 2017 worldwide.¹ This makes myasthenia gravis the most common neuromuscular transmission disorder.²

Ocular myasthenia gravis occurs when the extrinsic ocular muscles are involved.² Ocular muscle weakness can cause symptoms such as ptosis (dropping of the upper eyelid) or binocular diplopia (double vision).³ Ocular symptoms are common in those with myasthenia gravis.² Some patients with myasthenia gravis have only ocular symptoms.² However, for more than 80% of the those with ocular symptoms only at the onset of myasthenia gravis, weakness spreads to other muscle groups at some point.² One retrospective cohort study has indicated that early intervention for ocular myasthenia gravis was associated with the decrease in the frequencies of ocular symptoms and the delay or potential prevention of the occurrence of generalized myasthenia gravis.⁴

The diagnosis of ocular myasthenia gravis is not an easy task when ptosis is the only ophthalmic symptom.³ A series of tests can be used to diagnose ocular myasthenia gravis, such as serum antibodies, the tensilon test, and electromyography (EMG).⁵ These exams are not always able to identify the patients with ocular myasthenia gravis. The detection of antibodies to muscle acetylcholine receptors or the muscle-specific receptor tyrosine kinase in the serum can be useful in identifying cases,¹ but antibodies do not present in all patients, rendering the antibody test ineffective for some.³ The tensilon test has a sensitivity around 80% and uses edrophonium, a drug that blocks acetylcholinesterase and reverse muscle weakness temporarily.³ However, edrophonium can cause life-threatening side effects, such as hypotension and bradycardia.³ EMG uses repetitive nerve stimulations to detect decreasing amplitude with repetitive stimulation.³ Single-fibre EMG is used to detect variability between individual muscle fibres within a motor unit.³ By measuring the jitter of the muscle fibres, single-fibre EMG can determine whether acetylcholine release is within normal ranges and the neuromuscular transmission functions well.⁶ One major disadvantage of EMG is that it requires electrodes inserted in the target muscles.³ The invasive nature of this test can prevent patients from being examined.³

Recently, video-oculography, a non-invasive test that tracks eye movements using video cameras, has been used in medicine for a few indications.⁷ There is some evidence showing that eye-tracking technology, such as video-oculography, can be used for the diagnosis of ocular myasthenia gravis.⁸ With the potential to avoid side effects of invasive procedures and prevent generalized myasthenia gravis, there is a need to review the diagnostic accuracy and cost-effectiveness of video-oculography for the detection of ocular myasthenia gravis, as well as the clinical guidelines regarding the use of eye-movement analysis (video-oculography) for suspected myasthenia gravis.

Research Questions

1. What is the comparative diagnostic accuracy of eye-movement analysis using video-oculography versus single fibre electromyography (EMG) for detection of ocular myasthenia gravis?

2. What is the comparative cost-effectiveness of eye-movement analysis using video-oculography versus single fibre EMG for detection of ocular myasthenia gravis?
3. What are the evidence based guidelines regarding the use of eye-movement analysis using video-oculography for suspected ocular myasthenia gravis?

Key Findings

No relevant evidence regarding the comparative diagnostic accuracy or cost-effectiveness of video-oculography versus single fibre electromyography for the detection of ocular myasthenia gravis was identified. There were no evidence-based guidelines providing recommendations on the use of video-oculography for the detection of ocular myasthenia gravis. Further research on the use of video-oculography for the diagnosis of ocular myasthenia gravis, compared with current methods, such as electromyography, may help to reduce the uncertainty regarding its use in clinical practice.

Methods

Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE via Ovid, EMBASE via Ovid, the Cochrane Library, the University of York Centre for Reviews and Dissemination (CRD) databases, the websites of Canadian and major international health technology agencies, as well as a focused Internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were video-oculography and myasthenia gravis. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2009 and May 27, 2019.

Selection Criteria and Methods

One reviewer screened citations and selected studies. In the first level of screening, titles and abstracts were reviewed and potentially relevant articles were retrieved and assessed for inclusion. The final selection of full-text articles was based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Population	Adults with suspected ocular myasthenia gravis
Intervention	Eye-movement analysis using video-oculography
Comparator	Single fibre electromyography (EMG)
Outcomes	RQ1: Diagnostic accuracy (e.g., velocity, amplitude, sustained gaze, ptosis, diplopia in primary and downward gaze) RQ2: Cost-effectiveness RQ3: Guidelines
Study Designs	Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, economic evaluations, and guidelines

EMG = electromyography; RQ = research question

Exclusion Criteria

Articles were excluded if they did not meet the selection criteria outlined in Table 1, they were duplicate publications, or were published prior to 2009. Guidelines with unclear methodology were also excluded.

Critical Appraisal of Individual Studies

No relevant evidence regarding the video-oculography for the detection of ocular myasthenia gravis was identified; therefore, critical appraisal was not conducted.

Summary of Evidence

Quantity of Research Available

A total of 323 citations were identified in the literature search. Following screening of titles and abstracts, 296 citations were excluded and 27 potentially relevant reports from the electronic search were retrieved for full-text review. No potentially relevant publications were retrieved from the grey literature search for full text review. Of these potentially relevant articles, 27 publications were excluded for various reasons, and no publications met the inclusion criteria and were included in this report. Appendix 1 presents the PRISMA⁹ flowchart of the study selection.

References of potential interest are provided in Appendix 2.

Summary of Findings

Diagnostic accuracy of video-oculography

No relevant evidence regarding the comparative diagnostic accuracy of video-oculography compared with EMG for the detection of ocular myasthenia gravis was identified; therefore, no summary can be provided.

Cost-Effectiveness of video-oculography

No relevant economic evaluations regarding the use of video-oculography for the detection of ocular myasthenia gravis compared with EMG were identified; therefore, no summary can be provided.

Guidelines

No relevant evidence-based guidelines regarding the use of video-oculography for the detection of ocular myasthenia gravis were identified; therefore, no summary can be provided.

Limitations

One major limitation was that there was no relevant evidence regarding the video-oculography for the detection of ocular myasthenia gravis identified. Video oculography remains infrequently used in the diagnosis of medical conditions.⁷ There was one clinical study and one case series that were identified to use eye-tracking technology in patients with myasthenia gravis, but studies did not compare with EMG.⁸

Conclusions and Implications for Decision or Policy Making


No relevant evidence regarding the use of video-oculography for the detection of ocular myasthenia gravis compared with EMG was identified. Based on the search, eye-tracking technology was studied only in two primary studies that recruited seven and two patients with myasthenia gravis^{8,10}. In these studies, EMG was not used as comparison.^{8,10} No relevant evidence-based guidelines providing recommendations on the use of video-oculography for the detection of ocular myasthenia gravis were identified.

The diagnostic accuracy and cost-effectiveness of video-oculography for the detection of ocular myasthenia gravis remains unclear. Further clinical trials on the use of video-oculography for the diagnosis of ocular myasthenia gravis, compared with current methods, such as electromyography, may help to decrease the uncertainty in clinical practice.

References

1. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. *BMC Neurol*. 2010;10(1):46.
2. Evoli A, Antonini G, Antozzi C, et al. Italian recommendations for the diagnosis and treatment of myasthenia gravis. *Neurol Sci*. 2019;40(6):1111-1124.
3. Azri M, Young S, Lin H, Tan C, Yang Z. Diagnosis of Ocular Myasthenia Gravis by means of tracking eye parameters. *Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine & Biology Society*. 2014;2014:1460-1464.
4. Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. *J Neurol*. 2009;256(8):1314-1320.
5. Leff DR, James DR, Orihuela-Espina F, et al. The impact of expert visual guidance on trainee visual search strategy, visual attention and motor skills. *Front Hum Neurosci*. 2015;9:526.
6. Laguëny A. [Single-fibre electromyography]. *Rev Med Liege*. 2004;59 Suppl 1:141-149.
7. Newman-Toker DE, Saber Tehrani AS, Mantokoudis G, et al. Quantitative video-oculography to help diagnose stroke in acute vertigo and dizziness: toward an ECG for the eyes. *Stroke*. 2013;44(4):1158-1161.
8. Mihara M, Kakeue K, Fujita K, Tamura R, Hayashi A. Quantification of fixation stability of upward gaze in myasthenia gravis by using an eye-tracking system. *Invest Ophthalmol Vis Sci*. 2016;57 (12):4576.
9. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol*. 2009;62(10):e1-e34.
10. Rutkove S, Malik W. Visual tracking technology in myasthenia gravis: A new quantitative biomarker. *Muscle Nerve*. 2017;56 (3):648.

Appendix 1: Selection of Included Studies



Appendix 2: Additional References of Potential Interest

Recommendations without Systematic Methodology

Evoli A, Antonini G, Antozzi C, et al. Italian recommendations for the diagnosis and treatment of myasthenia gravis. *Neurol Sci.* 2019;40(6):1111-1124.

Reviews without systematic literature searches

Azri M, Young S, Lin H, Tan C, Yang Z. Diagnosis of Ocular Myasthenia Gravis by means of tracking eye parameters. *Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine & Biology Society.* 2014;2014:1460-1464.